July 17, 2026
3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Compounded forms of semaglutide and tirzepatide were being sold by dozens of compounded pharmacies from August to October 2025, months after the FDA declared an end to compounding for those drugs, researchers reported. As Healio previously reported, the FDA removed tirzepatide (Mounjaro/Zepbound, Eli Lilly) from its drug shortage list in December 2024 and semaglutide from its drug shortage list
July 17, 2026
3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Troubling Findings in Study of GLP-1 Compounders

Sun Pharma gets go-ahead to sell generic semaglutide in South Africa

Why Semaglutide is an inflection point for India’s generics sector?

Sun Pharma gets nod from South African regulator for generic semaglutide injection

Adoption of generic semaglutide depends on the delivery device

Sun Pharma gets SAHPRA approval for generic semaglutide injection in South Africa for type 2 diabetes

Semaglutide sustains lower calorie intake for more than a year, study shows

Study Finds Some Medical Spas Still Selling Compounded Weight-Loss Drugs From Pharmacies With Regulatory Concerns

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with…